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The estimated central blood volume (i.e., blood 
volume in the heart cavities, 1- and central arterial 
tree) wao debnubed by mdtiplying cardiac output by 
ckmlato4 mean traneit time in 19 patients with 
cirrhosis and compared with sympathetic nervous 
activity and circulating level of atrial natriuretic 
factor. Arterial norepinephrine level, an index of 
overall sympathetic nervous activity (3.08 nmoW in 
patienta VB. 1.36 nmoUL in controls; p c 0.01) was 
xmgatively correlated (r = -0.64, p < 0.01) with eeti- 
mated central blood volume (mean = 23 mUkg in pa- 
tients w. 27 mUlrg in controh, p < 0.06). Similarly, 
renal m o u e  norepinephrine level (an index of renal 
eympathetic tone; 4.26 nmoW in patients va. 1.78 
PlplOvL in controh p < 0.01) was invemwly correlated 
with estimated central blood volume (r = -O.M, 
n = 18, p c 0.02). No mignificant correlation could be 
edddbhd between arterial atrial natriuretic factor 
level (8.9 pmoUL in patients VB. 9.6 pmoW in wntrok, 
not cdgnMcant) and estimated central blood volume. 
-c valuem were mbmquently m&ed with 
oral propranolol (80 mg). During padrenergic 
blockade, the mean eatimated central blood volume 
w ~ n d d ~ d g n i f i c a n t l y , e X c e p t  ineixpetientawho 
exhibited demewaa in mean arterial blood p- 
(86 to 68 mm He; n = 6 )  and decreaeee in mean 
emtimated central blood volume (23.2 to 20.6 mulrg; 
n = 6, p c 0.05). Slight i n c r e w  were observed in 
mean mt atrial pressure (2.2 to 3.7 mm He; n = 14, 
p c O.Ob)r this c- wae positively correlated with 
the change in estimated central blood volume 
(r=O.44, n =  14, p=O.W). In conclusion, reduced 
eetimafed central blood volume probably “unloads” 
volume mceptora and baromceptors, thua provoking 
enhanced overall and renal sympathetic nervous ac- 
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tivity and thereby contributing to incremed water 
and ealt retention in c i r r h d .  During padrenerglc 
blockade estimated central blood volume c w  
correlated with alterations in preload and aiterload. 
Thaw indicate that central circulatory and 
arterial undedlling le a key element of the hemo- 
dynamic derangement observed in cirrhosis. (HEPA- 
TOLOGY 1@8!&6: 1163- 1170.) 
We recently found that the estimated central blood 
volume (ECBV, i.e., blood volume in the heart cavities, 
lungs and central arterial tree) is decreased in patients 
with cirrhosis (1, 2), indicating a reduced “effective” 
blood volume. It has been postulated that central 
hypovolemia is responsible for the activation of the 
sympathetic nervous system and alterations in other 
homeostatic regulators, including atrial natriuretic 
factor (ANF), in these patients (3-7), but no study has 
addressed that question directly. 
Systemic and splanchnic hemodynamic values are 
altered during p-adrenergic blockade: reductions in 
portal venous pressure and cardiac output and increases 
in peripheral vascular resistance and right atrial 
pressure are seen. Because the ECBV may be deter- 
mined with these variables (1,2), we decided to measure 
ECBV after propranolol intake. 
This study was undertaken to assess the relationship 
between ECBV, systemic and portal hemodynamica and 
markers of overall and renal sympathetic nervous 
activity. We measured the ECBV and the circulating and 
renal venous levels of norepinephrine, arterial epi- 
nephrine and ANF before and after p-adrenergic 
blockade in patients with cirrhosis and esophageal 
varices who were undergoing hemodynamic investi- 
gation. 
PATIENTS AND METHODS 
Study Populution. Nineteen patients (17 men) with biopsy- 
verified cirrhosie were referred for hernodynamic i n d -  
gation. All patients had endoscopically veded esophageal 
varices; none had experienced bleeding episodes. Liver dieease 
waa caused by alcohol in 18 patients and poethepatitic in 
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FIG. 1. Relationship between ECBV and hepatic venous pressure 
gradient. 
one. The age range was 30 to 69 yr (mean = 58 yr). None of the 
patients had encephalopathy worse than grade 1. All were 
abstaining from alcohol intake and were without withdrawal 
symptoms at the time of study. Six patients were in Child- 
Turcotte group A, eight were in group B and five were in group 
C. Ultrasonography showed the presence of ascites in 11 
patients. Patients without ascites had no dietary restrictions, 
whereas those with ascites were prescribed a 40 mmol 
sodiumlday diet. In the group of patients with ascites, 11 
received spironolactone (100 mg/day), as monotherapy in 1 and 
in combination with bumetanide, 1 to 8 mglday, in 10. 
Biochemical test values are summarized in Table 1. The mean 
height was 170 cm (range = 163 to 182 cm), the mean body 
weight was 68 kg (range = 54 to 85 kg) and the mean body 
surface area was 1.82 m2 (range = 1.61 to 2.18 m2). 
Sixteen subjects (12 men) who were without abnormal 
findings (normal volunteers, n = 3; functional heart murmur, 
n = 3) or had only minor disorders (fatty liver, n = 8; fibrosis 
without cirrhosis, n = 2) served as controls for ECBV deter- 
mination (2). The control patients were fitted with catheters to 
rule out organic heart disease or portal venous hypertension. 
None showed evidence of organ failure or fluid accumulation, 
and all had normal chest appearance on x-ray, normal EKGs 
and normal levels of serum creatinine and electrolytes. Their 
age range was 37 to 76 yr, their body height range was 160 to 
180 cm, their body weight range was 42 to 99 kg and their body 
surface area range was 1.40 to 2.17 m2. 
Nine other subjects served as controls for assay of arterial 
and renal venous catecholamines (eight were men; six of these 
subjects were normal volunteers, two had fatty liver and one 
had a functional heart murmur). Their ages ranged from 22 to 
52 yr (5). The controls for assay of circulating ANF were eight 
people (four women) with no abnormal hernodynamic findings 
(three had irritable bowel syndrome and one each had 
intercostal neuralgia, myositis, postcholecystedomy pain and 
persistent hepatitis and fatty liver); they were fitted with 
catheters to rule out portal hypertension or mesenteric 
ischemia. Their ages ranged from 48 to 68 yr. 
TABU 1. Biochemical teet  value^^ in 19 patients 
with cirrhosis 
Mean 
Biochemical test (range) Normal range 
Serum bilirubin (pmoVL) 32 (7-115) 2-17 
10-40 Serum AST (IU/L) 66 (29-150) 
Serum alkaline phos- 380 (211-807) 50-275 
Prothrombin index 0.69 (0.29-1.51) 
Serum sodium (mmoVL) 137 (130-144) 136-147 
phatase (UL) 
0.7-1.3 
3.5-5.0 Serum potassium (mmoUL) 3.9 (3.4-5.2) 
Serum creatinine (pmoVL) 85 (55-136) 
Serum albumin 
49-121 
pmoUL 487 (288-666) 540-800 
37-55 33.6 (19.9-46) 
women, 7.1-9.9; 
men, 8.1-10.9 
f@L 
Hemoglobin (mmoUL) 8.2 (6.9-9.8) 
All subjects consented to the study, which was approved by 
the Ethics Committee for Medical Research in Copenhagen. No 
complications or side effects were encountered. 
h t o c o l .  Cardiac output, plasma volume, blood volume, 
pressure measurements and assessment of ECBV were per- 
formed as specified in the following paragraphs. The “ideal” 
body weight (IBW), expressed in kilograms of IBW (kg*), was 
estimated as 
IBW (kg*) = (H - 100) - f (H - 150) 
where H is body height in centimeters (8). 
Plasma samples for determination of endogenous norepi- 
nephrine, epinephrine and ANF were obtained as described 
elsewhere (1, 5, 7). 
The above procedures were performed in a basal period and 
were repeated during p-adrenergic blockade 90 min after 
ingestion of propranolol (80 mg). As a control of the time 
courses of arterial norepinephrine and epinephrine levels, 
ANF and ECBV, these variables were determined twice with 
the same time interval in other cirrhotic patients who were not 
receiving propranolol but were otherwise undergoing the same 
catheterization procedure. No significant changes were found. 
Catheterization. All subjects were studied in the morning 
after overnight fasting and after at least 1 hr in the supine 
position. Catheterization of the right atrium and the hepatic 
and renal veins was performed as described earlier (2, 5). A 
Cournand catheter (USCI; C.R. Bard Ireland Ltd., Galway, 
Ireland) or Swan-Ganz catheter (7F) (Baxter Healthcare 
Corp., Irvine, CA) was guided to the right atrium and hepatic 
and renal veins through the femoral route under fluoroscopic 
control while the patient was under local anesthesia. An 
indwelling polyethylene catheter was introduced through the 
femoral artery by the Seldinger technique, and the catheter tip 
was placed at the aortic bifurcation. Pressures were measured 
with a capacitance transducer (Simonsen & Weel, Copen- 
hagen, Denmark). The zero reference was the midaxillary 
level. 
Determination of Flow and Volume. Total plasma volume, 
whole blood volume, and cardiac output were determined as 
described elsewhere (1,2). ECBV was assessed according to the 
kinetic theory as cardiac output multiplied by the mean 
indicator transit time (1,2, 9-11). The latter is the mean time 
of indicator sojourn in the central vascular bed (9), determined 
as the time-weighted area under the arterial indicator curve 
and correded for the arterial catheter transit time (1, 2). 
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TABLE 2. ECBV and hernodynamic vduea in supine and fasting cirrhotic patients and controls 
Cirrhotic patients controlm 
(n = 16) p value Characteristics (n = 19) 
~ 
ECBV (1) 
ECBV (mvkg*) 
ECBV (% of blood volume) 
Mean transit time of central circulation (sec) 
Total blood volume (1) 
Total blood volume (mukg.) 
Total plasma volume (1) 
Total plasma volume (mUkg*) 
cardiac output ~Wmin)  
Heart rate (min-1) 
Arterial blood pressure (n = 18; mm Hg) 
@BbliC 
Diastolic 
Mean 
Systemic YBBCular resistance, (n = 18; dyn . sec/cm5) 
Right atrial pressure (n = 14; mrn Hg) 
Hepatic venow pressure gradient (mm Hg) 
1.51 t 0.29 
22.9 t 4.6 
27 t 6.0 
14.0 t 4.1 
5.73 t 0.98 
81 t 15 
3.76 t 0.72 
58 -+ 12 
6.81 t 1.7 
77 t 11 
135 f 22 
62 t 10 
84 t 16 
1,067 t 302 
2.2 t 2.2 
18.6 t 4.7 
1.81 t 0.40 
27.2 t 6.8 
33 f 5.5 
20.0 t 6.1 
5.45 t 1.15 
81 t 19 
3.27 t 0.58 
49 t 8.1 
5.22 t 1.5 
68 f 9 
141 t 22 
71 t 13 
95 t 13 
1,490 ? 510 
3.5 If: 2.7 
3.8 t 1.6 
< 0.02 
< 0.05 
< 0.01 
< 0.005 
NS 
NS 
< 0.05 
< 0.02 
< 0.01 
< 0.02 
NS 
< 0.05 
c 0.05 
c 0.01 
< 0.05 
< 0.001 
Data expressed as mean t S.D.; *expressed per kg estimated ideal body weight. 
Catheter transit time was determined as catheter volume 
divided by catheter flow rate during blood sampling (0.5 d s e c )  
(2). 
As indicator, 5 pCi of 1261-labeled human serum albumin 
(Institute of Energy Technique, yjeller, Norway) was injected 
quantitatively as a bolus through the venous catheter while the 
tip waa located at the junction of the right atrium and the 
inferior vena cava. Arterial samples (500 ~ 1 )  were collected 
with a calibrated pump (Dich, Copenhagen, Denmark) every 
second for 60 sec. Standards and blood samples were counted 
in a well-type scintillation counter (LKB-Wallace, Stockholm, 
Sweden); at least 10,000 counts were recorded per sample. The 
coefficient of variation of duplicate determination of ECBV in 
six cirrhotic patients was 8.8% (2). 
Plaama Catecholamines. Blood samples were collected from 
an artery and the right renal vein in ice-chilled tubes 
containing EGTA. Plasma was separated immediately from 
cells by centrifugation at 4" C and stored at - 70" C until it 
could be assayed. Plasma concentrations of endogenous nor- 
epinephrine and epinephrine were determined with an enzy- 
matic isotope derivative technique described previously (12). 
The intraassay and interassay coefficients of variation were 
approximately 7% and 11% for norepinephrine and epi- 
nephrine, respectively. 
ANF. Blood samples (10 ml) were collected from an artery 
into iaAdled tubes containing aprotinin (5,000 KTU) and 
heparin (500 IU). Plasma was immediately separated from 
blood cells by centrifugation at 4" C and frozen ( - 25" C) until 
it could be assayed. ANF in plasma was determined on RIA as 
described elsewhere (13, 14). The intraassay and interassay 
coefficients of variation were less than 10% and 15%, respec- 
tively. 
stati.tiwl &whation. Paired and unpaired Student's t 
teats and one-way ANOVA were used for group comparisons. 
Correlations were performed according to the least-squares 
method; p < 0.05 was considered significant. 
RESULTS 
Boecrl period. Results of assays for ECBV and other 
hernodynamic variables are summarized in Table 2. The 
ECBV and mean transit time of the central circulation 
were significantly decreased in patients with cirrhosis 
compared with controls (ECBV mean = 22.9 mvkg* in 
cirrhotic patients vs. 27.2 mVkg* in controls, p < 0.05; 
mean transit time: 14 sec in cirrhotic patients vs. 20 sec 
in controls, p < 0.005). The patients taking diuretic 
drugs had a slightly smaller mean ECBV than did those 
patients who were not taking diuretic drugs, but this 
difference was not statistically significant (22.0 2 1.2 
mvkg* (S.E.M.) vs. 24.2 2 1.9 ml/kg*, respectively; NS). 
ECBV was inversely correlated with increased hepatic 
venous pressure gradient in the patients (r = -0.62, 
p < 0.01; Fig. 1). Total plasma volume and cardiac 
output were increased, whereas mean arterial blood 
pressure and systemic vascular resistance were de- 
creased in the patient group (Table 2). 
As shown in Table 3, arterial plasma norepinephrine 
levels were significantly increased in patients compared 
with levels in controls (3.08 nmoUL vs. 1.36 nmoVL; 
p < 0.01). The mean renal venous norepinephrine con- 
centration in the cirrhotic patients was significantly 
higher than the mean arterial concentration (4.26 
n m o n  vs. 3.08 nmoVL; n = 18, p < 0.001) and signif- 
icantly higher than the mean r e d  venous norepi- 
nephrine level in the controls (4.26 nmoVL vs. 1.78 
nmoVL; p < 0.01). The cirrhotic patients had a mean 
arterial norepinephrine level that was inversely corre- 
lated with ECBV (r = -0.54, p < 0.01; Fig. 2A); pa- 
tients with normal arterial values of norepinephrine 
(i.e., less than 2.2 nmoVL; n = 8) had a significantly 
higher mean ECBV than did patients with increased 
norepinephrine levels (26.3 2 1.7 vs. 21.4 2 0.9; 
n = 11, p < 0.02). Renal venous norepinephrine level 
was also inversely correlated with ECBV in the patient 
group (r = -0.53, n = 18, p < 0.02; Fig. 2B). Plasma 
epinephrine and ANF levels were normal in our cirrhotic 
patients (Table 31, and no significant relationship was 
found between ECBV and ANF concentration (r = 0.18, 
NS; Fig. 3) or epinephrine level. 
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pAdrenergic Blockade. p-Adrenergic blockade pro- 
duced a substantial decrease in heart rate and cardiac 
respectively; Table 4). The mean transit time of the 
central circulation increased significantly (+28%; 
p < 0.005), but the mean ECBV was not altered signif- 
icantly after propranolol ingestion, except in six pa- 
tients. These patients had a decrease in mean arterial 
blood pressure (from 85 mm Hg to 69 mm Hg) and a 
decrease in mean ECBV (from 23.2 ml/kg* to 20.6 
m&$; p < 0.05). The mean hepatic venous pressure 
gradient decreased (from 18.6 to 16.3 mm Hg; n = 19, 
p < 0.011, but no significant correlation with ECBV was 
seen after propranolol ingestion (r = -0.13; NS). A 
slight increase in the mean right atrial pressure (from 
2.2 mm Hg to 3.7 mm Hg; n = 14, p < 0.05) was 
output (-20% [p < 0.0013 and -24% [p < 0.0011, 
:. 
. 
. 
. *. 
a 
I I 20 r -  pmol/l 
0 10 
artorlal ANF conc. 
FIG. 3. Relationship between ECBV and arterial plasma concen- 
tration of ANF (r = 0.18; NS). 
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Contra1 artorlal troo 
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FIG. 4. Schematic illustration of ECBV, consisting of the volumes 
of the heart cavities, the pulmonary vascular bed and the central 
arterial tree. I,, I8 and I ,  are mean transit times for right heart, 
lungs, left heart and central arterial tree, respectively; X€,, = sum 
of individual transit times; ECBV, = segment of the central blood 
volume. Hatched area illustrates arteriovenous shunt. For details, 
see Appendix. 
observed during p-adrenergic blockade. This change was 
positively correlated with the change in ECBV (r = 0.44, 
p = 0.06). 
Arterial norepinephrine and epinephrine levels in- 
creased significantly &r propranolol ingestion (Table 
41, but no significant correlation with ECBV was found. 
ANF did not change significantly and was not correlated 
with ECBV durjng P-adrenergic blockade; nor was any 
change in M,, norepinephrine or epinephrine level 
correlated with change in ECBV. 
DISCUSSION 
The arterial plasma level of norepinephrine is an index 
of overall sympathetic nervous activity in patients with 
cirrhosis (5, 15-17). In this study, ECBV was inversely 
correlated with arterial norepinephrine concentration, 
which means that the more reduced the ECBV, the more 
enhanced the sympathetic nervous tone. This rela- 
tionship may not be causal-for example, ECBV and 
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TABLE 3. Circulating levels of catecholaminem and ANF in supine, fasting patienta with cirrhoaia and in Oontrok 
Cirrhotic patients Controls 
CatecholamineslANF (n = 19) (n = 9) p Value 
Norepinephrine 
In arterial plasma (nmoVL) 
In renal venous plasma (nmoVL) 
Epinephrine in arterial plasma (nmoVL) 
ANF in arterial plasma (pmoVL) 
3.08 t 1.53O 
4.26 r 2.426 
0.43 e 0.27 
8.9 ? 4.9 
1.36 2 0.36 < 0.01 
1.78 ? 0.49 < 0.01 
0.27 2 0.16 NS 
9.6 2 5.7' NS 
"Data expressed as mean 2 S.D. 
bn = 18. 
=n = 8. 
TABLE 4. Effect of p-adrenergic blockade on hernodynamic values and nenrohumoral markem in 19 cirrhotic pathta 
Change from b a d  value 
Characteristics AbsoluW Percentage p value 
Heart rate (min-') -15 2 9 - 20 < 0.001 
Cardiac output (L/min) - 1.64 5 0.88 - 24 < 0.001 
ECBV (1) -0.02 0.36 - 1  NS 
Mean transit time of central circulation (sec) +3.7 2 3.9 + 28 < 0.005 
Total blood volume (1) -0.15 2 0.80 - 3  NS 
Total plasma volume (1) +0.07 ? 0.45 + 2  NS 
Mean arterial blood pressure (n = 18; mm Hg) -4.8 2 11.0 - 6  CO.1 
Systemic vascular resistance, (n = 18; dyn . sec/cm5) 
Hepatic venous pressure gradient (mm Hg) -2.3 -t 3.7 - 15 < 0.01 
Arterial norepinephrine (nmoVL) iO.37 2 0.36 + 13 < 0.01 
Arterial epinephrine (nmol/L) +0.43 ? 0.65 + 90 < 0.01 
Arterial ANF (pmoUL) t 1.9 2 5.4 + 21 NS 
+209 e 180 + 28 < 0.01 
+ 1.5 2 1.6 + 60 < 0.05 Right atrial pressure (n = 14; mrn Hg) 
"Data expressed as mean ? S.D 
norepinephrine level could both be related to pro- 
gression of liver disease (5, 18). However, it should be 
borne in mind that a well-established reflex arc links 
volume receptors and baroreceptors to postganglionic 
sympathetic burst frequency in humans and animals 
(19, 20). It is thus likely that central vascular under- 
filling activates volume receptors and baroreceptors, 
thereby contributing to the enhanced sympathetic 
nervous activity found in patients with cirrhosis. 
Moreover, this study showed a significant inverse 
correlation between the size of the ECBV and the renal 
venous norepinephrine level. This finding suggests that 
the central underfilling contributes directly to enhanced 
sympathetic activity in the kidneys, because the level of 
renal venous norepinephrine is closely related to nor- 
epinephrine spillover from the kidney and thereby 
related to the renal sympathetic nervous tone (5,21,22). 
It is now well established that renal sympathetic 
overactivity contributes to the reduced renal blood flow 
and increaeed sodium and water retention in patients 
with decompensated cirrhosis (4, 16, 23). Effects of 
diuretic drugs on sympathetic nervous activity and 
ECBV are modest and have been considered in detail 
elsewhere (2, 5). 
In contrast to the sigdicant relationship between 
decread  ECBV and enhanced sympathetic nervous 
tone, we found no relationship between ECBV and 
circulating level of ANF. ANF has been reported to be 
reduced, normal and increased in the presence of 
cirrhosis (1, 7, 24-26). Arterial ANF concentration was 
normal in this study. Plasma ANF level is increased in 
patients with congestive heart failure and in subjects 
with volume expansion and increased atrial pressure 
(27, 28). It is low or normal in people with hypovolemia 
(27, 29). The normal ANF levels and the absence of 
correlation with ECBV found in our patients suggest 
that atrial volume is not affected substantially by ECBV 
reduction. This point of view is in keeping with recent 
reports by Rector et al. (30,311, who actually found an 
insignificant decrease in right atrial volume ( - 5 ml) and 
a significant increase in left atrial volume ( + 16 ml) in 
patients with cirrhosis. Another possibility is that the 
presence of ascites alters spatial relationships in the 
heart (32, 331, thereby rendering the release of ANF 
more or less independent of the size of ECBV. Fur- 
thermore, decreased clearance of ANF in the presence of 
reduced release may also account for the unchanged 
plasma concentration. This possibility, however, seem 
less likely because recent reparts suggest that clearance 
of ANF is normal in cirrhosis (34, 35). 
The time sequence of the development of abnormal 
distribution of blood volume in cirrhotic patients is not 
known. In an experimental model of portal hyper- 
tension, Groszmann (36) recently showed that the initial 
event is reduced systemic vaecular resistance. Cardiac 
output does not increase until plasma volume expansion 
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has taken place. As further evidence of the importance 
of peripheral vasodilatation, it should be mentioned that 
normalization of sodium and water excretion may not 
only require expansion of the central blood volume but 
also normalization of the low arterial blood pressure 
(17). 
p-Adrenergic blockade induced substantial changes in 
systemic vascular resistance and portal pressure. The 
decrease in the hepatic venous pressure gradient and the 
increase in systemic vascular resistance (both toward 
normal values) might be expected to cause an increase in 
ECBV (1, 2). Propranolol decreased cardiac output and 
increased right atrial pressure. However, in spite of 
these major hemodynamic alterations ECBV was almost 
unchanged and was decreased only in those patients who 
experienced decreases in mean arterial blood pressure. 
This indicates to us that arterial blood pressure is an 
important determinant for the size of ECBV and stresses 
the fact that ECBV includes the central parts of the 
arterial tree. Moreover, reduced arterial blood pressure 
may not only bring about reduced arterial blood volume 
but also a decrease in the volumes of the heart cavities 
and vascular bed of the lungs through decreased af- 
terload (37). Finally, propanolol may modify ECBV by 
changing the circulating level of vasoactive factors; this 
may influence central vascular tone (18). 
During p-adrenergic blockade, the inverse rela- 
tionship between ECBV on one hand and hepatic venous 
pressure gradient, arterial norepinephrine level and 
renal venous norepinephrine level on the other hand 
disappeared. This may have been a result of direct action 
exerted by propranolol on the hepatic venous pressure 
gradient and on sympathetic nervous activity, whereas 
the alteration in ECBV may have been governed largely 
by changes in preload and afterload. A direct rela- 
tionship was observed between the change in right atrial 
pressure and the change in ECBV after propranolol 
ingestion. In a previous study we found no relationship 
between ECBV size and right atrial pressure (2). In this 
context it should be recalled that the level of right atrial 
pressure relative to an external reference in the midax- 
illary line does not necessarily reflect the transmural 
atrial pressure and the filling of the central vascular bed. 
However, by relating the change in ECBV to the change 
in right atrial pressure we obtained a measurement 
independent of the external pressure reference. 
Patients with cirrhosis have decreased systemic vas- 
cular resistance because of arteriolar dilatation and 
opening of arteriovenous shunts in almost all vascular 
territories (4, 38, 39). The potential effect of these 
hemodynamic alterations on the assessment of the 
ECBV is considered in the appendix. As the appendix 
illustrates, evenly distributed peripheral vasodilatation 
or arteriovenous shunting in all vascular territories is 
not likely to influence determination of ECBV. Con- 
versely, the presence of a large central arteriovenous 
shunt may result in a slightly overestimated value of 
ECBV. In a previous report, we considered the potential 
effects of intracardiac shunts and portopulmonary 
shunting on the determination of ECBV (2). Pulmonary 
shunts have no effect on the assessment of ECBV (2,40). 
In conclusion, patients with cirrhosis are unable to 
maintain a normal size of central and arterial blood 
volume (“effective” blood volume). Reduced central and 
arterial blood volume most likely “unload” volume 
receptors and baroreceptors and thus provoke enhanced 
overall sympathetic nervous activity and increased 
sympathetic tone in the kidney. p-Adrenergic blockade 
resulted in substantial hemodynamic changes but only 
modest changes in the central and arterial blood volume. 
However, these changes were correlated with alterations 
in preload and afterload, indicating that central circu- 
latory underfilling is an integral part of the hemody- 
namic derangement observed in cirrhosis. 
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APPENDIX 
Determination of ECBV may be influenced by circu- 
latory shunts (2). Patients with cirrhosis have derrsased 
peripheral vascular resistance; this may be due in part to 
the presence of systemic arteriovenous shunts (4, 46, 
47). The influence of general arteriolar vasodilatation 
and arteriovenous shunting on the determination of 
ECBV is noted below. The effect of a shunt is discussed 
in relation to the fundamental kinetic equation: 
volume = mean transit time (f) x flow (12). 
Exampk A. Assuming that cardiac output (CO) is 
6.0 Wmin and the parts of ECBV are 150 ml, 650 ml, 
150 ml and 350 ml for right heart, lungs, lee heart 
and central arterial tree, respectively (see Fig. 41, the 
segmental mean transit times (ZJ will be f1 = 60 x 
0.150/6.0 = 1.5 sec; fz = 6.5 sec; i3 = 1.5 sec; and 
5, = 3.5 sec. The sum of segmental mean transit 
times (Xi,) = 1.5 sec + 6.5 sec + 1.5 sec + 3.5 88c = 
13.0 sec, and thereby ECBV = 2fn - CO = 13.0 * 6.0 - 
103/60 = 1,300 ml. This value is equal to the sum of 
segmental central blood volumes SECBV,, = 
150 ml + 650 ml + 150 ml + 350 ml = 1,300 ml. 
Ezampk B. It may be assumed that peripheral 
vascular resistance is decreased because of wideapread 
arteriolar dilatation or the opening of numerous arte- 
riovenous shunts in all vascular territories, which are 
assumed to be evenly distributed in all systemic vas- 
cular areas. If CO increases to 9.0 Urnin, the segmental 
transit times wil l  be f1 = 6.0 - 0.150/9.0 = 1.0 sec; f2 = 
4.33 sec; f, = 1.0 sec; and f, = 2.33 sec. Hence 
Xin  = 1.0 sec + 4.33 sec + 1.0 sec + 2.33 sec = 8.66 
sec and ECBV = Zf, - CO = 8.66 - 9.0 * 103/60 = 1,299 
ml. Here also is agreement between ECBV as deter- 
mined from f and cardiac output and that determined 
from the sum of the volumes in the single segments 
(ZECBV), even though f decreased from 13.0 sec to 8.66 
sec because of the hyperkinetic circulation. 
Ezample C. As another example it may be assumed 
that hyperdynamic circulation is due to the presence of 
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a large arteriovenous shunt with a flow of 3.0 L/min (Fig. 
4). In this case, CO also increases from 6.0 to 9.0 Wmin. 
As in the foregoing example, f ,  = 1.0 sec; E2 = 4.33 sec; 
and E3 = 1.0 sec. In contrast, only 6.0 Wmin passes 
through the nonshunt segments of the peripheral 
circulation. Thus E4 will be the same size as it is in 
example A f4 = 3.5 sec. Consequently, f, = 1.0 
sec + 4.33 sec + 1.0 sec + 3.5 sec = 9.83 sec, a value 
larger than that in example B (8.66 sec). ECBV = 
Zf, - CO = 9.83 - 9.0 - 103/60 = 1,475 ml. This value 
is larger than ZECBV,, = 150 ml + 650 ml + 150 
ml + 300 ml = 1,300 ml. This is because here the 
volume of blood contained in the arterial tree up to 
points that are temporally equidistant from the heart to 
the aortic bifurcation includes a “shunt volume” 
= E4‘ - shunt flow = 3.5 - 3.0 - lO3/6O = 175 ml. If the 
shunt is centrally located and the shunt flow is high, the 
shunt volume may include parts of the blood volume 
located on the venous side of the circulation. 
In conclusion, ECBV, as determined with our method, 
is not likely to be influenced by widespread arteriolar 
dilatation or opening of arteriovenous shunts in almost 
all vascular territories. In contrast, our method may 
overestimate the actual value of the ECBV in the 
presence of a distinct systemic arteriovenous shunt. The 
size of the overestimation will depend on the size of the 
shunt flow relative to CO and on the location of the 
shunt. More centrally located shunts will lead to more 
overrated values for ECBV than will more peripherally 
located shunts, other factors being equal. However, 
as illustrated in example C, the overestimation 
(175/1,475 = 12%) is relatively modest, even in the 
presence of a relatively high flow (3.0 L/min/6.0 
Wmin = 50%) in a centrally located shunt. 
